Compare KLXE & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLXE | PMVP |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 76.8M |
| IPO Year | 2018 | 2020 |
| Metric | KLXE | PMVP |
|---|---|---|
| Price | $3.48 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 339.6K | ★ 395.0K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $636,600,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $0.85 |
| 52 Week High | $4.50 | $1.88 |
| Indicator | KLXE | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 44.84 |
| Support Level | $1.69 | $1.09 |
| Resistance Level | $4.07 | $1.50 |
| Average True Range (ATR) | 0.42 | 0.08 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 21.79 | 31.67 |
KLX Energy Services Holdings Inc is a growth-oriented provider of diversified oilfield services to onshore oil and natural gas exploration and production (E&P) companies operating in both conventional and unconventional plays in all of the active basins throughout the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Southwest region.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.